CA
CMPX icon

Cliff Asness’s Compass Therapeutics CMPX Stock Holding History

Cliff Asness’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.69M Buy
3,509,137
+3,308,709
+1,651% +$9.77M ﹤0.01% 1730
2026
Q1 		$1.06M Buy
200,428
+45,210
+29% +$261K ﹤0.01% 2731
2025
Q4 		$834K Buy
155,218
+96,070
+162% +$444K ﹤0.01% 2649
2025
Q3 		$207K Buy
59,148
+10,697
+22% +$33.8K ﹤0.01% 3247
2025
Q2 		$126K Buy
+48,451
New +$99.9K ﹤0.01% 3140

Other funds holding CMPX

California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Cliff Asness's CMPX Position: Q2 2026 in Review

Cliff Asness increased its Compass Therapeutics (CMPX) stake by 1,651% in Q2 2026, buying an estimated $9.77M and bringing the position to 3,509,137 shares worth $7.69M. The position accounts for ﹤0.01% of the portfolio, ranked #1730.

Cliff Asness first reported a position in CMPX in Q2 2025 and has held it in 5 quarters since. 214 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Cliff Asness held 3,509,137 shares of Compass Therapeutics worth $7.69M as of Q2 2026.
  • Cliff Asness bought 3,308,709 Compass Therapeutics shares in Q2 2026, an estimated $9.77M.
  • Compass Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #1730 holding.
  • Cliff Asness first reported a position in Compass Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 214 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.